US 7,455,991 B2
	Serpentine transmembrane antigens expressed in human cancers and uses thereof
Daniel E. H. Afar, Brisbane, Calif. (US); Rene S. Hubert, Los Angeles, Calif. (US); Arthur B. Raitano, Los Angeles, Calif. (US); Douglas Saffran, Encinitas, Calif. (US); and Steven Chappell Mitchell, Gurnee, Ill. (US)
Assigned to Agensys, Inc., Santa Monica, Calif. (US)
Filed on Jan. 05, 2004, as Appl. No. 10/752,421.
Application 10/752421 is a division of application No. 09/455486, filed on Dec. 06, 1999, granted, now 6,833,438.
Application 09/455486 is a continuation in part of application No. 09/323873, filed on Jun. 01, 1999, granted, now 6,329,503.
Prior Publication US 2005/0063975 A1, Mar. 24, 2005
This patent is subject to a terminal disclaimer.
Int. Cl. C07H 21/02 (2006.01); C12N 15/63 (2006.01)

U.S. Cl. 435—69.1  [536/23.1; 435/320.1]

6 Claims

1. An isolated polynucleotide selected from the group consisting of (a) a polynucleotide comprising the sequence as shown in FIG. 9 (SEQ ID NO: 5), wherein T can also be U; (b) a polynucleotide comprising the sequence as shown in FIG. 9 (SEQ ID NO: 5), from nucleotide residue number 356 through nucleotide residue number 1717, wherein T can also be U; (c) a polynucleotide encoding a polypeptide comprising the sequence of the STEAP-2 polypeptide encoded by the cDNAs contained in the plasmid deposited with American Type Culture Collection as Accession No. PTA-311; and (d) a polynucleotide encoding a STEAP-2 protein comprising the amino acid sequence as shown in FIG. 9 (SEQ ID NO: 6).